152 related articles for article (PubMed ID: 1394342)
1. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.
Brusa P; Dosio F; Pietribiasi F; Delprino L; Feraiorni P; Mariani M; Bussolati G; Cattel L
Cancer Immunol Immunother; 1992; 35(6):373-80. PubMed ID: 1394342
[TBL] [Abstract][Full Text] [Related]
2. Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.
Brusa P; Pietribiasi F; Bussolati G; Dosio F; Arione R; Comoglio PM; Prat M; Cattel L
Cancer Immunol Immunother; 1989; 29(3):185-92. PubMed ID: 2659170
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice.
Brusa P; Dosio F; Pacchioni D; Delprino L; Grosa G; Bussolati G; Cattel L
J Pharm Sci; 1994 Apr; 83(4):514-9. PubMed ID: 8046606
[TBL] [Abstract][Full Text] [Related]
4. Intratumour therapy of solid tumours with ricin-antibody conjugates.
Kanellos J; McKenzie IF; Pietersz GA
Immunol Cell Biol; 1989 Apr; 67 ( Pt 2)():89-99. PubMed ID: 2786496
[TBL] [Abstract][Full Text] [Related]
5. Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.
Cattel L; Delprino L; Brusa P; Dosio F; Comoglio PM; Prat M
Cancer Immunol Immunother; 1988; 27(3):233-40. PubMed ID: 3263208
[TBL] [Abstract][Full Text] [Related]
6. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
FitzGerald DJ; Bjorn MJ; Ferris RJ; Winkelhake JL; Frankel AE; Hamilton TC; Ozols RF; Willingham MC; Pastan I
Cancer Res; 1987 Mar; 47(5):1407-10. PubMed ID: 3493065
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
[TBL] [Abstract][Full Text] [Related]
9. Application of anti-sialyl Lea monoclonal antibody, KM231, for immunotherapy of cancer.
Shitara K; Hanai N; Kusano A; Furuya A; Yoshida H; Wada K; Watanabe T; Sato S
Anticancer Res; 1991; 11(6):2003-13. PubMed ID: 1776833
[TBL] [Abstract][Full Text] [Related]
10. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
11. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain.
Trown PW; Reardan DT; Carroll SF; Stoudemire JB; Kawahata RT
Cancer Res; 1991 Aug; 51(16):4219-25. PubMed ID: 1868442
[TBL] [Abstract][Full Text] [Related]
12. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
13. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
14. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
15. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.
Rostaing-Capaillon O; Casellas P
Cancer Immunol Immunother; 1991; 34(1):24-30. PubMed ID: 1722138
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
Calvete JA; Newell DR; Wright AF; Rose MS
Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer.
Zangemeister-Wittke U; Collinson AR; Fisch I; Jones RM; Waibel R; Lehman HP; Stahel RA
Int J Cancer; 1993 Jul; 54(6):1028-35. PubMed ID: 8392978
[TBL] [Abstract][Full Text] [Related]
18. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Schmidberger H; King L; Lasky LC; Vallera DA
Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258
[TBL] [Abstract][Full Text] [Related]
20. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]